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Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging contributor to biofilm-related
infections. We recently reported that strains lacking sigma factor B (sigB) in the USA300 lineage of CA-MRSA are unable to
develop a biofilm. Interestingly, when spent media from a USA300 sigB mutant was incubated with other S. aureus strains,
biofilm formation was inhibited.Followingfractionation and mass spectrometry analysis, the major anti-biofilm factor identified
in the spent media was secreted thermonuclease (Nuc). Considering reports that extracellular DNA (eDNA) is an important
componentofthe biofilm matrix,weinvestigatedthe regulationandrole ofNuc in USA300. Theexpressionofthenucgene was
increased in a sigB mutant, repressed by glucose supplementation, and was unaffected by the agr quorum-sensing system. A
FRET assay for Nuc activity was developed and confirmed the regulatory results. A USA300 nuc mutant was constructed and
displayedanenhancedbiofilm-formingcapacity,andthenuc mutantalsoaccumulatedmorehigh molecularweighteDNA than
the WT and regulatory mutant strains. Inactivation of nuc in the USA300 sigB mutant background partially repaired the sigB
biofilm-negative phenotype, suggesting that nuc expression contributes to the inability of the mutant to form biofilm. To test
the generality of the nuc mutant biofilm phenotypes, the mutation was introduced into other S. aureus genetic backgrounds
and similar increases in biofilm formation were observed. Finally, using multiple S. aureus strains and regulatory mutants, an
inverse correlation between Nuc activity and biofilm formation was demonstrated. Altogether, our findings confirm the
important role for eDNA in the S. aureus biofilm matrix and indicates Nuc is a regulator of biofilm formation.
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Introduction
Staphylococcus aureus is an opportunistic pathogen capable of
causing a diverse spectrum of acute and chronic infections.
Methicillin-resistant S. aureus (MRSA) has received considerable
attention due to reports that invasive MRSA infections are
surpassing other infectious agents as a cause of death [1]. Over the
past decade, the healthcare challenge has worsened with an
epidemic wave of MRSA in the community, also called
community-associated MRSA or CA-MRSA. These strains are
known for causing severe invasive infections not seen in previous
epidemic waves of antibiotic resistance [2,3].
The emergence of CA-MRSA has led to a growing number of
reports that these strains are also an important cause of chronic
disease, such as infective endocarditis [4], osteomyelitis [5,6], and
foreign body infections [7]. The common theme of these various
chronic infections is adherence to a host surface and persistence in
the presence of immune defenses and antibacterial therapy.
Generally, these types of persistent communities are considered to
be growing as biofilms, defined as surface-attached communities of
cells encased in an extracellular polymeric matrix that are more
resistant to antimicrobial agents.
With a recent surge in studies on S. aureus biofilms, our
knowledge of the properties of these structured communities
continues to develop. One area of recent interest is the matrix
material, which displays significant divergence across the Staph-
ylococci. The polysaccharide intercellular adhesin (PIA) is a
dominant component of the Staphylococcus epidermidis biofilm matrix
[8], but there are increasing reports that PIA is less important in
the matrix of methicillin-susceptible S. aureus (MSSA) and MRSA
biofilms [9,10,11,12,13]. In contrast, many reports have docu-
mented a critical role for proteinaceous material in the S. aureus
matrix [9,13,14,15,16,17,18,19,20]. S. aureus produces multiple
extracellular proteases with self-cleavage activity that can detach
cells from surfaces [9,17,19,21], supporting the proposal of a
protein-based matrix.
An emerging view of S. aureus biofilms is that extracellular DNA
(eDNA) has an important structural role in the matrix composition
[8,13,22,23]. There is growing appreciation for the contribution of
eDNA in a wide range of bacterial biofilms, including Pseudomonas
aeruginosa [24,25,26], Bacillus spp. [27,28], Haemophilus influenzae
[29], Neisseria spp. [30,31], Enterococcus faecalis [32,33], and Listeria
monocytogenes [34]. For S. aureus, the source of matrix eDNA is
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lysis of a subpopulation of cells [22,23]. In an intriguing analysis of
the S. aureus eDNA composition, Izano et al. used a range of
restriction enzymes to demonstrate that fragments of at least 11 kb
are required to maintain biofilm integrity [8], suggesting the
eDNA has to be of sufficient size to serve as effective matrix
material.
We have previously shown that S. aureus mutants lacking the
stress-response alternative sigma factor B (SigB) are unable to form
biofilms [12]. Genetic or chemical inhibition of extracellular
protease activity restored biofilm capacity [12,16]. This observa-
tion led to our initial hypothesis that the increased protease
production in sigB mutants, which has also been observed with sarA
mutants [14,15], contributed to the biofilm-negative phenotype. In
this report, we utilized a biochemical approach to continue our
analysis of secreted factors that impact biofilm formation. In
contrast to our expectation that a specific protease(s) would be
identified, this approach identified secreted nuclease in the spent
media of a CA-MRSA sigB mutant as a potent anti-biofilm agent.
For decades, it has been known that S. aureus secretes a
thermostable nuclease enzyme, and this activity is highly
conserved among clinical isolates and has been used as a marker
for direct detection of S. aureus in blood cultures [35]. The enzyme
is referred to by many different names, such as micrococcal
nuclease, thermonuclease, deoxyribonuclease and DNase, and
hereafter we will refer to the enzyme as ‘‘nuclease’’ or ‘‘Nuc.’’ Due
to its ease of purification [36], the Nuc protein became a favorite
among enzymologists and crystallographers, leading to numerous
kinetic, protein folding and structural studies [37,38,39,40,41]. By
the time S. aureus molecular genetic techniques emerged in the
1980’s, interest in Nuc had waned, and less is known about the
biological contribution of this enzyme. Herein, we examined the
regulation of the nuc gene and present a new role for the encoded
enzyme in biofilm maturation.
Results
Fractionation of LAC spent media identifies secreted
nuclease as an anti-biofilm factor
We recently demonstrated that sigma factor B (sigB) is essential
for biofilm formation in S. aureus in both the MSSA strain SH1000
and the CA-MRSA strain ‘‘LAC’’ [12]. Strain LAC is a member
of the pulse field gel electrophoresis (PFGE) type ‘‘USA300’’,
which is the dominant clone of the CA-MRSA [42]. Strain LAC
has been the subject of extensive transcriptional, proteomic, and in
vivo pathogenic analysis [43,44,45], and we have continued studies
on this strain as a model for USA300 chronic infection. The
reason for the biofilm negative phenotype of the LAC sigB mutant
is unknown, but we reasoned that increased levels of extracellular
proteases were contributing to this phenotype. To investigate this
possibility, we prepared cell-free spent media from LAC sigB and
discovered that the presence of this spent media inhibited biofilm
formation by other wild-type S. aureus strains. For this experiment,
we used the SigB proficient model strain SH1000 [46], which is a
strong biofilm former in microtiter based assays [9,12] and thus
served as a standard to test anti-biofilm activity of spent media. As
shown in Figure 1A, as little as 10 mL of spent media from the
LAC sigB mutant inhibited biofilm formation of SH1000. To rule
out the possibility of detachment mediated by autoinducing
peptide (AIP) present in the culture supernatant [9], an agr mutant
(SH1001) unresponsive to AIP was used as the test strain, and the
same inhibition of attachment was observed. We concluded that
the LAC sigB mutant was secreting one or more anti-biofilm
factors independent of AIP.
In an initial attempt to identify the secreted factor, the spent
media of the LAC sigB mutant was fractionated by anion-
exchange chromatography. When column fractions were assayed
for their ability to inhibit microtiter plate biofilm formation by
SH1001, only the flow-though fractions contained anti-biofilm
activity, indicating the unknown factor was cationic. Spent media
was fractioned on cation-exchange resin, and two dominant peaks
of anti-biofilm activity were identified through microtiter biofilm
testing with strain SH1001 (Fig. 1B). These peaks were active
beyond two layers of standard deviation in the microtiter biofilm
assay. The samples were separated by SDS-PAGE to visualize
protein content, and the first active fraction contained two protein
bands of ,14 and 19 kDa, respectively, and the second contained
one ,16 kDa protein (Fig. 2A). Each of these three protein bands
was excised from the SDS-PAGE gel, subjected to trypsin
digestion, and the peptide fragments were then identified by
MALDI mass spectrometry. Following database comparison, the
14 kDa band was identified as chemotaxis inhibitory protein
(CHIPS), while the 16 and 19 kDa proteins were identified as
different-length forms of the secreted Nuc enzyme (Fig. 2B). Based
on the original Nuc naming convention, the longer form of Nuc
released by signal peptidase processing is called ‘‘NucB’’ [39]. This
protein has a pI of ,9.3 and elutes from the cation-exchange
column first. The shorter processed form of the enzyme called
‘‘NucA’’ has a higher pI of ,9.5 and elutes later during cation
exchange. The processing event removes 19 amino acids from the
amino-terminal end and is catalyzed by an unknown protease
(Fig. 2B). Considering Nuc was identified in both peaks of anti-
biofilm activity, and the processed form of Nuc was pure in the
second peak, we concluded that Nuc was the secreted factor in
LAC sigB mutant spent media that inhibited biofilm attachment.
To confirm this finding, purified Nuc enzyme (Worthington
Biochemicals) was tested with SH1001 in a microtiter biofilm
assay. Similar to testing of the fractionated spent media, Nuc
enzyme blocked biofilm formation in a dose-dependent manner
(data not shown).
Regulation of nuclease gene expression
Knowing that the Nuc enzyme could inhibit biofilm develop-
ment, we hypothesized that S. aureus regulates this enzyme in order
to control eDNA levels for biofilm maturation. To evaluate Nuc
regulation, we developed an enzyme activity based on fluorescence
resonance energy transfer (FRET) (see Methods and Materials for
additional details). The assay was verified using purified Nuc
enzyme, and as anticipated, the assay responded in a dose-
dependent manner to Nuc (data not shown). Purified enzyme used
to generate a standard curve for calculation of activity units
throughout this report. Nuc enzyme activity levels were measured
in sigB and agr global regulatory mutants in the SH1000 and LAC
genetic backgrounds (Fig. 3A & 3B). In sigB mutants, Nuc levels
were up ,240-fold in SH1000 and 11.5-fold in LAC. Contrary to
our expectations, inactivation of agr had no adverse effect on Nuc
activity levels.
To expand on these regulatory studies, time courses were
performed in LAC WT and regulatory mutants using media with
and without glucose supplementation. Addition of glucose to
growth media is a common practice used to simulate biofilm
forming conditions for S. aureus, and cells grown in media without
supplemental glucose do not form biofilms [9]. Throughout the
time course, transcription of the nuc gene was monitored with a
promoter fusion to sGFP (plasmid pCM20), Nuc activity levels
were measured with the FRET-based assay, and the pH of the
media was determined. As anticipated from published reports
[47], the pH dropped during logarithmic growth as the glucose
Nuclease Modulates Biofilm Formation
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significant difference was observed in the pH profiles of any of the
strains tested (data not shown). In the presence of excess glucose,
the pH dropped to ,5 for each strain, and did not recover to a
neutral pH in the time frame of the experiment (data not shown).
Like many extracellular enzymes, expression of nuc correlated with
growth. Transcription of nuc in the WT strain, as measured by the
Pnuc-GFP reporter, was first detected during logarithmic growth
and continued into early stationary phase (Fig. 3C). Likewise,
extracellular Nuc enzyme, as measured using the FRET activity
assay, was first detected during logarithmic growth and continued
to accumulate into earlier stationary (Fig. 3D), reaching 1955 U/
ml at the end of the time course. Supplementation of the media
with 0.4% glucose repressed nuc transcription (Fig. 3C) and
prevented Nuc enzyme from accumulating (Fig. 3D), although
trace activity (0.2–0.5 Units/ml) was detected during early
logarithmic growth before dropping to undetectable levels. In
the absence of supplemental glucose, the timing of nuc transcrip-
tion and accumulation of Nuc enzyme by the sigB mutant was
similar to that of WT, except the sigB mutant accumulated several
fold more transcript (Fig. 3E) and Nuc enzyme (Fig. 3F), reaching
7670 U/ml at the end of the time course. The effect of 0.4%
supplemental glucose on nuc expression was significantly attenu-
ated in the sigB mutant. Nuc activity levels were still quite high,
reaching 660 U/ml in late logarithmic growth and remaining in
the 660–860 U/mL range through the end of the time course
(Fig. 3FD). In contrast, and in support of the Nuc activity assays in
Fig. 3B, nuc expression and enzyme activity profiles of the agr
mutant were identical to those of WT (data not shown).
Controlled nuc gene expression modulates biofilm
formation
Considering that Nuc levels are repressed during growth in
biofilm media, we hypothesized that controlled nuc expression
could impact biofilm formation. To investigated this hypothesis we
transformed tetracycline-inducible expression vectors containing
nuc into SH1001, a strain that normally produces low levels of Nuc
(Fig. 3A) and is a good biofilm former (Fig. 1A), and we tested
whether induction of nuc expression could disrupt biofilm
formation in flow cells and microtiter plates. In a flow cell
experiment with anhydrotetracycline (aTet) induction, the strain
harboring pALC2073-nuc failed to develop biofilm (Figure 4B),
whereas the strain harboring empty vector established a robust
biofilm (Figure 4A). Similarly in a microtiter plate biofilm assay,
Figure 1. Anti-biofilm activity of spent media from LAC sigB mutant. A. Cell-free spent media of strain AH1483 (LAC DsigB) was prepared and
varying amounts were incubated with SH1000 (white bars) or SH1001 (black bars) in microtiter biofilm assays. B. AH1483 spent media was
fractionated on cation exchange resin. Relative protein concentration (closed circles) in the fraction was approximated using Bradford reagent, and
each fraction was tested for inhibition of biofilm formation (closed triangles) using SH1001. Horizontal lines display biofilm formation for control wells
to which column equilibration buffer was added. The middle black line is the average biofilm formation, and the lines above and below indicate 1
(thin line) and 2 (dashed line) standard deviations from the mean. The two peaks of anti-biofilm activity (fractions 34–40 and 57–61) were more than 2
standard deviations from the mean.
doi:10.1371/journal.pone.0026714.g001
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decrease in biomass as the concentration aTet inducer was
increased, whereas SH1001 containing empty vector did not
(Fig. 4C). As anticipated, Nuc activity levels rose in conjunction
with the increased levels of aTet inducer (data not shown).
Coupled with the time course studies in Figure 3, it is evident that
glucose suppression of Nuc levels enhances biofilm formation and
distorting this regulatory event has a negative impact on biofilms.
Construction and characterization of a LAC nuc mutant
With an important role for Nuc in biofilm modulation being
revealed, we assessed the contribution of Nuc to biofilm formation
in strain LAC. A nuc mutant (AH1680) was constructed and
characterized using multiple different methods to assess Nuc
function. Using DNA agar plates, the secreted DNase activity was
markedly lower in the nuc mutant and restored in a complemented
strain (Fig. 5A). Nuc activity measured with the FRET assay was
almost undetectable in the mutant and overproduced ,10-fold in
the complemented strain (Fig. 5A). Using Nuc antibodies, secreted
Nuc protein was absent from the mutant and somewhat
overproduced in the complemented strain (Fig. 5A). The long
(NucB) and short (NucA) forms of nuclease were apparent in the
immunoblot for both WT and the complemented mutant strain,
while both bands were absent in the nuc mutant. As anticipated,
both long and short forms of Nuc are active as confirmed by DNA
zymography (Fig. S1A & S1B) and the FRET-based enzyme assay
(data not shown). To examine the processing of NucB to NucA,
the LAC sigB mutant was grown with protease inhibitors E64,
EGTA, and PMSF to inhibit the cysteine, metallo, and serine
classes of proteases. In an immunoblot (Supplementary Fig. 1C),
the longer NucB form of the enzyme was restored with E64,
suggesting a cysteine protease is contributing to the cleavage event,
and to a lesser extent, calcium chelation with EGTA also inhibited
the processing. Finally, exoprotein analysis by SDS-PAGE
indicated the only difference between the extracellular proteomes
of the WT, complemented and nuc mutant strains was the absence
of the Nuc protein bands in the mutant (data not shown).
Characterization of nuc mutants in other strain
backgrounds
To expand the Nuc studies beyond the LAC genetic
background, spent media from LAC and additional strains were
assayed for Nuc activity using the FRET-based assay and for the
ability to prevent biofilm formation using a SH1001 microtiter
assay. The strains tested were MSSA strains Newman [48] and
UAMS-1 [49]; hospital-associated MRSA isolate COL [50]; and
CA-MRSA isolates MW2 [51], SF8300 [52], and TCH1516 [53].
Some variability in Nuc activity was observed in the spent media
from cultures grown in TSB (Fig. 5B). The USA300 strains had
the highest Nuc levels, with LAC, SF8300 and TCH1516 all
accumulating approximately 1100 U/ml of activity. The Nuc
levels were 310 U/ml in COL, 585 U/ml in Newman, and
452 U/ml in UAMS-1, all substantially lower than the USA300
strains. MW2 had the lowest amount of Nuc (116 U/ml),
accumulating only 10% of the USA300 activity. The significantly
longer doubling times of Newman (46 min) and COL (64 min),
relative to that of the USA300 strains (32 min) [54], may account
for the lower Nuc accumulation in these strains. In contrast, the
low level in MW2 is indicative of altered growth-dependent
expression of nuc, since this strain has a doubling time similar to
USA300 strains [51]. The spent media from all the strains was
able to prevent biofilm formation by SH1001 (Fig. 5C), with high
Figure 2. Secreted nuclease (Nuc) is the anti-biofilm factor in LAC sigB spent media. A. The two major peaks of activity identified in cation-
exchange chromatography were separated by SDS-PAGE. Fraction numbers are listed on the top of the gels. The gel on the left shows peak 1 and on
the right shows peak 2. Protein bands were excised and identified by MALDI mass spectrometry as NucB and CHIPs in peak 1, and NucA in peak 2. B.
Schematic of nuclease protein domains. For NucA, only tryptic peptides corresponding to the blue colored residues were identified by MALDI
following trypsin digestion. The typtic peptide drawn in red was not observed. For NucB, the blue residues and the additional red colored residues at
the amino terminus were identified by MALDI. The indicated location of the cleavage event (between Ser and Ala) that yields the shorter NucA is
based on the report of Davis et al. [39].
doi:10.1371/journal.pone.0026714.g002
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Considering only ,12 U/ml Nuc is present in the MW2 spent
media sample following dilution, the amount of Nuc needed to
prevent SH1001 microtiter biofilm formation is less than this
amount.
To determine whether Nuc was contributing to the anti-biofilm
activity of spent media, nuc mutations were generated in each of
the strains assayed in Fig. 5B. After confirming the mutations
through molecular analysis, DNase agar plate assays, and FRET-
based activity assays (data not shown), the ability of spent media
from nuc mutant cultures to prevent biofilm formation by SH1001
was assayed. In all cases, when compared to the corresponding
WT control, the spent media from the nuc mutant had reduced
ability to prevent SH1001 biofilm formation (Fig. 5C). For the
USA300 (LAC, SF8300, TCH1516), Newman and UAMS- 1
strains, the amount of SH1001 biofilm formed in the presence of
nuc mutant spent media was statistically indistinguishable from the
untreated control, implying that Nuc could account for the
majority of the anti-biofilm activity observed with this assay. In the
presence of spent media from either the COL or MW2 nuc
mutants, the amount of SH1001 biofilm formed was more than
the corresponding WT media, but less than the untreated control.
To determine whether the nuc mutants share a common biofilm
deficient phenotype, microtiter plate assays were performed for
each WT strain and its nuc mutant counterpart (Fig. 5D). In all but
one case, the introduction of a nuc mutation resulted in a
significant enhancement of biomass accumulation. The only
exception to the enhancement phenotype was strain COL, which
was the weakest biofilm former of the group. The COL phenotype
could be due in part to the additional anti-biofilm activity that was
Figure 3. Regulation of Nuc levels in strain LAC. A. Extracellular Nuc activity of SH1000 and Dagr::Tet and DsigB mutants in this genetic
background. B. Extracellular Nuc activity of LAC and Dagr::Tet and DsigB mutants in this genetic background. Panels C–F represent timecourse results
with strain LAC. The Pnuc-sGFP promoter fusion (pCM20) was placed into LAC WT (C, D) and DsigB mutant (E,F), and the strains were grown in BHI
with and without 0.4% glucose supplementation. Plots of growth versus nuc GFP reporter are C, E. For labels of these plots, OD of growth in BHI
(black closed circles), OD of growth in BHI + glucose (red circles), nuc reporter in BHI (green triangles), nuc reporter in BHI + glucose (blue diamonds).
Plots of growth versus Nuc activity are D, F. The Nuc activity labels correlate with color coding of nuc reporter measurements, and the OD plots are
the same.
doi:10.1371/journal.pone.0026714.g003
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(Fig. 5C).
Flow cell biofilms of the LAC nuc mutant
We recently reported that a nuc mutation in the MSSA strain
UAMS-1 increases the biofilm forming capacity in a flow cell [22].
To learn whether CA-MRSA displays a similar phenotype, the
LAC WT, nuc mutant and complemented strains were grown in
flow cells, and biofilms were post-stained with the live cell stain
Syto9 and dead stain Toto3 to indicate eDNA and dead cells
(Fig. 6). The Toto3 dye was selected because its far-red emission
collection does not overlap with that of Syto9, and Toto3 has
increased sensitivity as compared to another common dead stain,
propidium iodide, in detecting eDNA [22]. Following confocal
fluorescence microscopy, we observed that average thickness of
biofilms was markedly increased in the nuc mutant (38.5 mm vrs.
18.1 mm for WT), and the WT phenotype was restored with
complementation of nuc on a plasmid (14.7 mm). We also observed
an increase in Toto-3 staining near the substratum of the nuc
mutant biofilm. This increase in Toto-3 staining could be
indicative of more eDNA at the initial point of bacterial
attachment, but this staining technique does not distinguish
between eDNA and dead cells.
High molecular weight eDNA accumulates in culture
media of the nuc mutant
Although expression of nuc is repressed under biofilm forming
conditions (Fig. 3), the LAC WT biofilm is still substantially
reduced when compared to the nuc mutant in microtiter (Fig. 5)
and flow-cell experiments (Fig. 6). We hypothesized that the nuc
mutant would accumulate eDNA, while residual Nuc activity in
the WT strain would degrade eDNA into smaller fragments,
negatively impacting biofilm formation. To assess eDNA accu-
mulation and fragment size, eDNA was isolated from media of
cultures grown with and without glucose supplementation and
separated in agarose gels (Fig. 7). Without excess glucose, eDNA
Figure 4. The effect of controlled nuc gene expression in biofilms. For images A and B, biofilms were grown in TSB supplemented with 0.2%
glucose and 100 ng/mL aTet and post-stained with Syto9. The nuc gene was expressed from an aTet-inducible promoter in plasmid pALC2073. A z
series of images were obtained with CLSM and reconstructed for the 3D rendering. Beneath each 3D reconstruction is a XZ cross-section of the
biofilm with each side of a grid square at 20 mm. A. SH1001 with pALC2073 (vector). B. SH1001 with pALC2073-nuc (nuc induction). For a dose-
response test (C), SH1001 with pRMC2 (vector) was compared to SH1001 with pRMC2-nuc (nuc induction) comparison in microtiter biofilm assays at
increasing aTet concentrations.
doi:10.1371/journal.pone.0026714.g004
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lower molecular weight (MW) DNA fragments (Fig. 7A). The
intensity of these smears is highest at the bottom of the gel under
5 kb in size, indicating that the majority of eDNA in these lanes is
low MW. In contrast, eDNA isolated from the nuc mutant is
similar in size to purified, high MW genomic DNA with minimal
degradation, and this phenotype can be complemented. In the sigB
mutant where Nuc levels are high, the eDNA is completed
Figure 5. Characterization of MSSA and MRSA nuc mutants. A. LAC WT, nuc mutant, and complemented strains were tested in three
conditions: DNase agar plates (top panels) with zones of clearing indicating secreted Nuc activity, Nuc enzyme activity measurement (middle panel),
and immunoblot for Nuc protein (bottom panel). The long form (NucB) and processed short form (NucA) are indicated. B. Extracellular Nuc activity of
various WT S. aureus strains. C. Effect of nuc mutant (black bars) and WT (white bars) spent media on inhibition of SH1001 biofilm formation. Values
are the average of 16 wells. Untreated control (n=36 wells) is shown on the left as a gray bar. D. Biofilm formation of nuc mutants (black bars) versus
WT strains (white bars). Values are the average of 8 wells.
doi:10.1371/journal.pone.0026714.g005
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flow cell biofilm conditions for 3 days. The biofilms were post-stained with Syto9 (live stain, green) and Toto3 (dead stain, red). Top-down and cross-
section CLSM images were taken for Syto9 (A, E, I) and Toto3 (B, F, J) channels. A merged image of these two channels was also prepared (C, G, K).
Finally, a z series of merged images was obtained for a 3D reconstruction of the biofilm (D, H, L) and each side of a grid square is 20 mm.
doi:10.1371/journal.pone.0026714.g006
Figure 7. Accumulation of high MW eDNA in the nuc mutant. The eDNA was purified from the spent media of LAC WT and strains with
mutations in the nuc, agr, and sigB loci. A nuc complement (+ nuc) and nuc sigB double mutant was also included. A. Agarose gel of eDNA purified
from strains grown in TSB. B. Agarose gel of eDNA purified from strains grown in TSB with 0.4% glucose supplementation. In each gel, lane ‘‘SM’’ is a
DNA size marker with a top size of 12 kb. Purified chromosomal DNA was included as a control and is shown in the lane labeled ‘‘genomic’’.
doi:10.1371/journal.pone.0026714.g007
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mutation.
With excess glucose, a high MW band of eDNA is again
observed for the nuc mutant and the nuc sigB double mutant
(Fig. 7B). Interestingly, WT and the agr mutant have increased
amounts of high MW eDNA compared to the low glucose
condition (Fig. 7B vrs. 7A), although some degradation was still
apparent, which consistent with trace Nuc activity accumulating in
the high glucose media. The eDNA in the sigB mutant and the
complemented nuc strain is degraded, presumably due to the high
levels of Nuc enzyme in both conditions. Taken together, these
experimental observations indicate that the nuc mutant accumu-
lates more high MW eDNA compared to WT and a sigB mutant,
and the introduction of the nuc mutation is dominant for this
phenotype in variant genetic backgrounds.
Removal of nuclease improves sigB mutant biofilms
With the apparent correlation of high Nuc levels to a biofilm-
negative phenotype, we hypothesized that inactivation of the nuc
gene in the sigB mutant background would restore biofilm-forming
capacity. The nuc sigB double mutant was constructed in the LAC
strain, and biofilm formation was compared to WT and single
mutants in nuc and sigB using flow cells. The controls behaved as
anticipated with WT forming a biofilm (Fig. 8A) and the nuc
mutant showing increased biomass accumulation (Fig. 8B), while
the sigB mutant formed no biofilm (data not shown), which is
consistent with our previous report that a sigB mutant is incapable
of forming a biofilm under flow-cell conditions [12]. In contrast,
the nuc sigB double mutant (Fig. 8C) formed a patchy biofilm
compared to WT and the nuc mutant. Based on COMSTAT
analysis, the average biomass of the nuc sigB double mutant
(11.1 mm
3/mm
2) was similar to WT (11.8 mm
3/mm
2), while the
average thickness was much reduced (4.3 mm vrs. 16.7 mm),
consistent with the uneven distribution of biofilm across the
surface. The ability of a nuc mutation to partially restore biofilm
formation in the sigB strain confirms that Nuc activity negatively
affects this phenotype. However, eliminating Nuc did not fully
restore sigB biofilm to a WT level, indicating that other factors also
contribute to the sigB phenotype.
Nuc vrs. biofilm correlation
In order to quantify the inverse relationship between Nuc
activity and biomass, microtiter plate biofilm assays were
conducted on strains containing mutations that modulate Nuc
activity in the LAC WT (Fig. 9A) and UAMS-1 (Fig. 9B) genetic
backgrounds. Nuc activity measurements were performed on the
filter-sterilized media removed from the microtiter plate wells
following growth, allowing for a direct comparison between Nuc
activity and biomass. The most notable finding is that the
logarithmic fits of the data demonstrate a quantitative relationship
between biomass and Nuc activity in the LAC WT and UAMS-1
backgrounds, and these fits are strikingly similar across genetic
backgrounds (Fig. 9). Several other observations are consistent
with the overall findings in this work: (1) nuc mutants accumulated
the most biomass, had the lowest measurable Nuc activity, and
complementation restored the WT phenotype; (2) a sigB mutant
had high Nuc activity and accumulated low levels of biomass, and
introduction of the nuc mutation restored the WT phenotype; (3)
agr mutants were similar to wildtype strains in both Nuc activity
levels and biomass; and (4) sarA regulatory mutants had high Nuc
activity and accumulated the least amount of biomass. Based on
these correlation plots, Nuc activity levels are a strong predictor of
biofilm formation across multiple S. aureus strain lineages.
Discussion
We observed that USA300 LAC sigB mutant spent media
contained potent anti-biofilm activity that counteracted the ability
of other wild-type S. aureus strains to develop biofilms. In this work,
we identified the source of this activity as the secreted Nuc enzyme
and further examined the regulation and role of Nuc in biofilm
maturation. The discovery of Nuc in the fractionation experiment,
and not proteases, was somewhat unexpected. Based on the recent
reports that proteases can disperse S. aureus biofilms [9,17,19], we
anticipated identifying proteolytic activity in the fractions that
blocked biofilm formation. Multiple reports have demonstrated
that overproduction or exogenous addition of SspA (V8) protease
cleaves fibronectin binding proteins, which are important in the
accumulation of biofilm biomass [19,21]. In particular, exogenous
addition SspA was found to prevent biofilm formation for various
strain lineages in a microtiter plate assay that uses uncoated plates
and glucose supplementation [19]. Given the similarities between
the microtiter assay employed in this report and the published
SspA work, we anticipated finding anti-biofilm activity in the spent
media associated with this protease. However, we failed to identity
SspA (pI=4.6) in any of the elution fractions from anion-exchange
chromatography or flow-through fractions from cation-exchange
chromatography.
Figure 8. Rescuing LAC sigB mutant biofilms with nuc mutation. The LAC WT (A), nuc mutant (B), and nuc sigB double mutant (C) strains were
grown in flow cell biofilm conditions for 2 days. The biofilms were post-stained with Syto9 (live stain, green) and ToPro3 (dead stain, red).
Representative 3D reconstruction and cross-section images from CLSM are shown. Each side of a grid square is 38 mm.
doi:10.1371/journal.pone.0026714.g008
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anti-biofilm fractions. First, it is possible that the concentration of
SspA (or other proteases) in the column fractions was too low to
prevent biofilm formation. Testing whether this is the case would
require a quantitative determination, similar to what we have
reported here for Nuc, of the minimal amount of exogenous SspA
(or other protease) required to prevent biofilm formation. Second,
a number of studies suggest that effects of proteases on biofilm
formation require the combined activities of multiple different
enzymes. Introduction of single protease mutations into the
SH1000 sigB background [12,17] or into the UAMS-1 sarA
background [15] failed to restore biofilm forming capacity to the
sigB mutant and sarA mutants, respectively. However, simulta-
neous introduction of the aur and splABCDEF mutations restored
biofilm forming capacity to the SH1000 sigB mutant [12], and the
addition of protease inhibitor cocktails restored biofilm-forming
capacity to the UAMS-1 sarA mutant [15]. Given these
observations, the failure of the fractionation experiment to
establish a link between proteases and anti-biofilm activity is
consistent with reports that the coordinated function of multiple
enzymes might be required. Lastly, it may be that under altered
biofilm assay conditions, such as coating a surface with matrix
proteins, SspA or other proteolytic enzymes would have more
impact on biofilm formation.
With a newly identified role for Nuc as a biofilm inhibitor, we
hypothesized that S. aureus must repress enzyme production during
biofilm formation. Regulatory studies using a promoter fusion
confirmed that the nuc gene was repressed by glucose supplemen-
tation, which is a common additive used by researchers to induce
biofilm formation [9,10,19,55]. As anticipated, mutations in sigB
lead to increased nuc expression and Nuc activity (Fig. 3),
confirming microarray studies on these mutants [56,57]. The
reason for the enhanced Nuc levels is unknown but could provide
future insights on nuc gene regulation. There has long been
speculation that Nuc, like other extracellular enzymes, is part of
the agr regulon [58,59]. Surprisingly, using both transcriptional
fusions and Nuc activity assays, we were unable to find a role for
agr in Nuc regulation at either the transcriptional or post-
transcriptional level. We are currently following up on these
observations to further understand Nuc regulation.
Considering that nuc is already repressed with glucose
supplementation, the question also remained as to why the nuc
mutant grew a thicker flow cell biofilm than the WT strain (Fig. 6).
It is important to note that even with glucose supplementation,
trace levels of Nuc activity (0.2–0.5 U/ml) were still detected in the
WT spent media. This Nuc activity difference is apparent when
looking at the eDNA that accumulates outside the cell. Higher
MW DNA accumulated in the nuc mutant (Fig. 7), and the length
of the eDNA isolated was predominantly over 10 Kb, in range of
the previously identified cutoff necessary to maintain intact
biofilms [8]. The trace Nuc activity in the WT media may also
explain the difference in biomass accumulation in WT vrs. nuc
mutants in the microtiter biofilm assay (Fig. 5D). We hypothesize
that enough high MW eDNA accumulates after 4 hours of growth
to allow for biofilm formation to occur. After this threshold point is
reached, further cell lysis is not required, perhaps explaining why
inhibition of lysis is most effective at the initial growth stages in
preventing biofilm formation [22]. Other aspects of the eDNA
isolation paralleled Nuc regulation studies, such as when Nuc
levels were high in a sigB mutant or in media without glucose, the
eDNA was digested into smaller fragments. Overall, these findings
confirm previous reports and demonstrate that eDNA must be
high MW in order to be an effective matrix material [8].
The information acquired on the control of nuc gene expression
may provide insight on the biofilm phenotypes observed for
various S. aureus strains and regulatory mutants. Our findings
demonstrate that Nuc levels are tightly correlated with biofilm
formation, and this correlation applies across different WT stains
(Fig. 5). The only strain that behaved differently was COL, which
failed to develop a biofilm in the microtiter assay. Further, the
spent media from a COL nuc mutant still retained anti-biofilm
activity (Fig. 5C). Whether this strain produces an additional anti-
biofilm factor, such as an extracellular protease or a second
nuclease, is not clear. Most S. aureus strains tested produced high
levels of Nuc, in particular USA300 isolates (Fig. 5B), which might
be a factor in the technical challenges of assaying for biofilm
formation using uncoated microtiter plates. Our findings also
suggest that conditions or mutations leading to distorted Nuc
regulation contribute to biofilm phenotypes (Fig. 9). For instance,
sigB mutants overproduce Nuc even in the presence of glucose
suppression (Fig. 3F), leading to the degradation of eDNA (Fig. 7B)
and the inability to form biofilms. We demonstrate that removal of
Nuc repairs these phenotypes and recovers biofilm capacity
(Fig. 7B and 8C), although not completely. It is already
appreciated that proteases are an important contributor to the
biofilm-negative phenotype of sigB and sarA mutants [12,14,15],
Figure 9. Correlation of Nuc activity with biofilm formation. Nuc activity of mutants in the LAC (A) and UAMS-1 (B) strain backgrounds was
measured and compared to the amount of biomass accumulated by each strain. Nuc activity was measured using a FRET assay and is displayed in U/
mL. Biofilm formation was assessed by measuring biomass accumulation in microtiter assays. Logarithmic fits were performed (shown as line on
plots) with similar results for each plot.
doi:10.1371/journal.pone.0026714.g009
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inability of sigB nuc mutants to form a wildtype level of biofilm
(Fig. 8C). This proposal would be consistent with our previous
observations that the reduction or elimination of protease activity
partially restored sigB mutant biofilms [12]. Taken together, we
conclude that S. aureus biofilm formation is simultaneously
impacted by high levels of Nuc and extracellular proteases.
However, in vivo confirmation of this proposal is not yet available.
Ongoing studies in our laboratories will begin to address these
questions.
Considering our observations and other published reports
[8,22,23], the release and utilization of eDNA as a matrix material
may be an underappreciated factor in the survival of S. aureus.
There is evidence in previous reports that eDNA is necessary for S.
aureus in vivo biofilm formation [23,60]. Although it has been
proposed that medical devices become coated with host matrix
proteins following implantation [61,62,63], a recent report
demonstrated that abolition of nuclease production partially
restores biofilm formation in a S. aureus sarA mutant even in the
presence of plasma protein and protease inhibitors [15], suggesting
there is potential for eDNA during in vivo chronic infection. There
are also a growing number of examples where eDNA is required
for in vivo biofilm formation by other bacterial pathogens [29,64].
While we have investigated the contribution of S. aureus Nuc to
modulating eDNA levels, the host nucleases could also be a
significant factor in vivo. DNase I is the most extensively distributed
host nuclease and the enzyme responsible for the majority of
DNase activity in blood [65]. In serum samples, reports of DNaseI
levels range from 65627 U/g protein [66], which corresponds to
0.004460.0018 U/ml, to higher estimates of 0.35660.410 U/ml
[66] and 2.4762.48 U/ml [67]. Given these low levels of activity,
it is not clear whether there are sufficient quantities of DNaseI to
impact S. aureus biofilm formation during infection. Clearly, more
in-depth studies on the role of eDNA and nuclease enzymes in vivo
are warranted.
Herein, we have presented evidence that Nuc levels have a
significant impact on in vitro biofilm formation in S. aureus. Whether
growth of biofilms on biotic surfaces will be equally affected by
Nuc remains to be determined. While it is challenging to relate in
vitro observations to pathogenesis in vivo, S. aureus is able to persist in
healthcare settings on the abiotic surfaces of fomites. There are
numerous examples of MSSA and MRSA strains being isolated
from hospital objects [68,69,70,71,72,73], and MRSA has the
ability to persist for periods up to 2 weeks on environmental
surfaces in hospitals [74,75]. Recent studies have demonstrated
that environmental contamination may contribute to the spread of
USA300 strains [76]. Whether eDNA release and modulation of
eDNA levels with Nuc will impact hospital surface colonization is
worthy of further exploration. With the growing recognition for
the role of eDNA in bacterial biofilms, the use of nuclease enzymes
as a potential means of controlling S. aureus attachment warrants
further study.
Materials and Methods
Bacterial strains and growth conditions
Bacterial strains and plasmids used are described in Table 1. E.
coli cultures were grown in Luria-Bertani (LB) broth or on LB agar,
and S. aureus strains were grown in tryptic soy broth (TSB) or on
tryptic soy agar (TSA) unless otherwise indicated. Difco methyl
green DNase test agar used to examine nuclease production in S.
aureus was purchased from BD (Sparks, MD) and prepared
according to manufacturer’s instructions. Plasmids in E. coli were
maintained using antibiotic concentrations (in mg/ml) of ampicillin
(Amp), 100. Plasmids in S. aureus were maintained using antibiotic
concentrations of chloramphenicol (Cam), 10; erythromycin
(Erm), 10; and tetracycline (Tet), 10, unless otherwise noted.
Strains were incubated at 37uC with liquid cultures shaken at 200
RPM. When required, the growth medium was supplemented
with glucose at concentrations of 0.2% or 0.4% W/V.
Recombinant DNA and genetic techniques
Plasmid DNA was prepared from E. coli and electroporated into
S. aureus RN4220 as previously described [77]. DNA was moved
from RN4220 into other S. aureus strains through transduction with
bacteriophage a80 or 11 [78]. All restriction enzymes and
enzymes for DNA modification were purchased from New
England Biolabs (Beverly, MA) and used according to manufac-
turer’s instructions. Oligonucleotides were synthesized by Inte-
grated DNA Technologies (Coralville, IA). Non-radioactive
sequencing was performed at the University of Iowa DNA
Sequencing Facility.
Plasmid construction
Nuclease promoter fusion. The nuclease promoter region
was amplified by PCR from AH1263 genomic DNA using
the oligonucleotides CLM400: 59 GTTGTTAAGCTTGTA-
AATTATAAGTTATACATCTCG 39 and CLM404: 59 GT-
TGTTGGTACCCTTTTTAGTTAATTTTAATATTAAACG
39. The PCR product was purified, digested by HindIII and KpnI
and ligated to pCM11 [13], also cut by the same enzymes. The
plasmid was confirmed by DNA sequencing. The nuc promoter
sGFP plasmid was designated pCM20.
Tetracycline-inducible vectors. The nuc gene was
amplified by PCR from AH1263 genomic DNA using the
following oligonucleotides: MRK24: 59 GTTGTTGGTACC-
ACTAAAAAGAAAGAGGTGTTAGTTATGACAGAATACT-
TATTA 39 and MRK25: 59 GTTGTTCTCGAGTTATTG-
ACTGAATCAGTGTCT 39. The PCR product was purified and
digested using the restriction enzymes SacI and KpnI, then ligated
to pALC2073 [79] and pRMC2 [80], also cut by SacI and KpnI.
The plasmids were confirmed by DNA sequencing and called
pALC2073-nuc and pRMC2-nuc, respectively.
Nuclease complementation plasmid. The nuc gene, along
with 360 bp of the upstream promoter region and 100 bp
downstream, was amplified by PCR from AH1263 genomic
DNA using the following oligonucleotides: MRK26: 59
GTTGTTGCTAGCGTAAATTATAAGTTATACATCTCG
39 and MRK27: 59 GTTGTTGAATTCAATACACTTA-
CTTTTGATACTATTTAC 39. The resulting PCR product
was digested using the enzymes NheI and EcoRI, then ligated to
pCM28 [81] cut by the same enzymes. Plasmid construction was
confirmed by DNA sequencing and called pCM28-nuc.
Construction of nuclease mutant
The nuclease mutant was constructed using the Targetron Gene
Knockout System (Sigma, TA0100). Primers (antisense at position
532/533) as designed by the Targetron Design Site are: CLM413:
59 AAAAAAGCTTATAATTATCCTTAAAGCTCCGTTTAG-
TGCGCCCAGATAGGGTG 39, CLM414: 59CAGATTGTA-
CAAATGTGGTGATAACAGATAAGTCCGTTTACCTAAC-
TTACCTTTCTTTGT 39, CLM415: 59 TGAACGCAAGTTT-
CTAATTTCGGTTAGCTTCCGATAGAGGAAAGTGTCT 39.
PCR was performed according to the Targetron protocol. The
PCR product was gel purified, digested by BsrG1 and HindIII and
ligated to the S. aureus Targetron donor plasmid pNL9164 (Sigma,
T6701) digested by the same enzymes. After electroporation into
E. coli, the colonies were screened by PCR and subsequently
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designated pNL-532. pNL-532 was electroporated into RN4220
and subsequently phage transduced into AH1263 at 30uC. An
overnight culture grown in TSB with Erm was diluted 1:100 in
fresh media and grown at 30uC to an optical density (OD) at
600 nm of 0.5. Addition of CdCl2 to 10 mM followed by growth at
30uC for 90 min induced expression from the cadmium promoter.
The cells were diluted and plated on TSA with Erm at 30uC.
Colony PCR was used to screen for insertions using oligonucle-
otides CLM400: 59 GTTGTTAAGCTTGTAAATTATAAGTT
ATACATCTCG 39 and CLM405: 59 CAGTGACACTTTTA-
CAATGAGC 39. Positive colonies showed a 900 bp insertion. To
cure the plasmid, an intron-positive colony was grown overnight at
42uC in TSB without antibiotic, plated and subsequently screened
for erythromycin sensitive colonies. The nuc::LtrB mutant was
designated strain AH1680.
Identification of anti-biofilm activity by chromatography
An overnight culture of strain AH1096 (LAC DsigB) was
inoculated 1:500 into 200 ml of TSB in a 1 L flask and grown at
37uC with shaking (200 rpm) for approximately 20 hr. Cells were
removed by centrifugation at 60006g for 15 min at 4uC, and the
Table 1. Strains and Plasmids.
Strain or Plasmid Description Source or reference
Strains
E. coli strains
BW25141 Cloning strain [88]
S. aureus strains
AH845 (LAC) USA300 CA-MRSA [44]
AH1012 SH1000 DsigB [12]
AH1263 USA300 CA-MRSA Erm
S (LAC*) [16]
AH1292 AH1263 Dagr::TetM This work
AH1483 AH1263 DsigB This work
AH1525 AH1263 sarA::Kan This work
AH1680 AH1263 nuc::LtrB This work
AH1921 AH1263 nuc::LtrB DsigB This work
COL HA-MRSA [50]
AH2496 COL nuc::LtrB This work
MW2 USA400 CA-MRSA [51]
AH2497 MW2 nuc::LtrB This work
Newman MSSA, Type 5 capsule producer [48]
AH2495 Newman nuc::LtrB This work
RN4220 Restriction deficient cloning host [89]
SF8300 USA300 CA-MRSA [52]
AH2498 SF8300 nuc::LtrB This work
SH1000 sigB
+ derivative of NCTC8325-4 [46]
SH1001 SH1000 Dagr::TetM [46]
SH1002 SH1000 sarA::Kan [46]
TCH1516 USA300 CA-MRSA [53]
AH2499 TCH1516 nuc::LtrB This work
UAMS-1 Osteomyelitis isolate [49]
UAMS-1471 UAMS-1 nuc [14]
UAMS-1472 UAMS-1471 + nuc [14]
UAMS-155 UAMS-1 agr::tet [14]
UAMS-929 UAMS-1 sarA::kan [14]
Plasmids
pALC2073 Tet inducible expression plasmid [79]
pALC2073-nuc pALC2073 with nuc cloned into SacI and KpnI sites This work
pCM20 pCE with Pnuc - sGFP This work
pCM28 pDB59 MCS [81]
pCM28-nuc pCM28 with nuc cloned into NheI and EcoRI sites This work
pRMC2 Low-range Tet inducible expression plasmid [80]
pRMC2-nuc pRMC2 with nuc cloned into SacI and KpnI sites This work
doi:10.1371/journal.pone.0026714.t001
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approximately 100-fold using Amicon Ultra-15 3 K centrifugal
filter units (Millipore, Bedford, MA) and dialyzed at 4uC against
10 mM sodium phosphate pH 6.5 (664 L) using dialysis tubing
with a 3350MW cut-off. Following dialysis the conditioned media
was concentrated to ,2.5 ml using an Amicon Ultra-15 3 K
centrifugal filter unit, and 2.4 ml was loaded onto a Toyopearl CM-
650M (Tosoh Biosciences, Tokyo, Japan) column (1 cm615 cm)
equilibrated with 10 mM sodium phosphate pH 6.5 at 4uC. The
column was washed with ,90 ml of 10 mM sodium phosphate
pH 6.5at a flow rateof ,1 ml/min until no protein wasdetectedin
the column effluent. Proteins were eluted using a 500 ml linear
gradientof0–0.3 MNaCl in10 mMsodiumphosphate pH 6.5at a
flow rate of ,1 ml/min. Elution fractions (a total of 90, ,5m l
elution fractions) were assayed for protein concentration by mixing
60 ml of the fraction with 200 ml of Bradford reagent and measuring
the OD at 595 nm. The anti-biofilm activity of all fractions (the 18
flow-through and 90 elution fractions) was determined using a 96-
well microtiter plate biofilm assay based on that previously
described [9]. Specifically 66% TSB supplemented with 0.2%
glucose was inoculated 1:1000 with an overnight culture of SH1001
and then 190 ml aliquots of this culture were transferred to wells of
96-well microtiter plates (Corning 3596) that contained 10 mlo f
each fraction. 18 control wells were included in the assay that
contained 10 ml of 10 mM sodium phosphate pH 6.5 and 190 mlo f
the SH1001 culture. Plates were incubated at 37uC with shaking
(200 r.p.m.) for 15 hr and cultures were removed by gentle
aspiration. Wells were washed twice with 200 ml of water, stained
for 10 min with 200 ml of 0.1% crystal violet in water, and washed
twice with 200 ml of water. Liquid was removed from the wells
following each wash or staining step by gentle aspiration. Following
the final wash, bound crystal violet was solubilized in 200 mlo f2 -
propanol and quantified by measuring OD at 615 nm.
Identifying proteins by mass spectrometry
Fractions identified as having anti-biofilm activity (elution
fractions 34–41 and 57–61) were analyzed by SDS-PAGE [82],
and the protein bands in these fractions were cut from the gels and
sent to the University of Iowa Proteomics Facility for identification
by mass spectrometry. Proteins were digested with trypsin and
extracted from the gels [83] and the resulting peptides were
analyzed by MALDI-TOF (matrix-assisted laser desorption/
ionization time-of-flight) mass spectrometry using a Bruker Biflex
III instrument. The identities of the proteins was determined by
submitting the mass spectrometric data for peptide mass
fingerprinting using MASCOT [84].
Development of a FRET based nuclease assay
Quantitative assays of nuclease activity typically measure the
release of acid soluble oligonucleotides following nuclease
digestion of DNA, with one unit of activity corresponding to a
change in optical density of 1.0 at 260 nm at 37uC and pH 8.0
[85]. We developed a simple Fluorescence Resonance Energy
Transfer (FRET) based assay capable of efficiently measuring the
nuclease activity in conditioned media over a large dynamic range.
The FRET substrate, a ‘‘PrimeTime
TM’’ qPCR probe purchased
from Integrated DNA Technologies (Coralville, IA), consists of a
short (15 mer) single-stranded oligonucleotide that is modified at
the 59 end with a Cy3 fluorophore and at the 39 end with Black
Hole Quencher 2 (BHQ2). The sequence of the substrate (59 CCC
CGG ATC CAC CCC 39) is the same as that reported by Lee
et al. [86], with an additional C at the 39 end. When the
oligonucleotide is intact, the Cy3 and BHQ2 are close enough that
fluorescence is quenched, but when the oligonucleotide is cleaved,
fluorescence from Cy3 is proportional to the amount of cleavage
and can be used to quantify nuclease activity. Fluorescence
measurements were made by mixing 25 ml of FRET substrate,
diluted to 2 mM in buffer consisting of 20 mM Tris pH 8.0 and
10 mM CaCl2, with 25 ml of conditioned media (diluted with TSB
as necessary) in the well of a microtiter plate (Corning), and
measuring the rate of fluorescence change (excitation 552 nm/
emission 580 nm) at 30uC in a Tecan Infinity 200 M plate reader.
Initial reaction velocities were determined by linear least-squares
fitting and converted to Units of Nuc activity per mL (U/mL)
using a standard curve that was generated using various amounts
of purified Nuc enzyme (0.1, 0.5, 0.025, 1.0, and 10 U/ml)
purchased from Worthington Biochemicals (Lakewood, NJ). Points
on the Nuc standard curve are the average of four kinetic
measurements. The units of nuclease activity reported here are
equivalent to reported values [85], where one unit of activity
corresponds to a change in optical density of 1.0 at 260 nm at
37uC, pH 8.0, with DNA as a substrate. The detection limit for
purified Nuc dissolved in growth media was found to be 0.015 U/
ml, using the assay conditions and procedure employ here
Growth dependent expression of nuc in LAC and LAC
mutants
Overnight cultures of strains AH1263 (WT), AH1292 (agr), and
AH1483 (sigB) grown in BHI were inoculated 1:1000 into 200 ml
of BHI or 200 ml of BHI supplemented with 0.4% glucose in 1 L
flasks. Cultures were grown at 37uC with shaking (200 rpm). At
designated times, approximately 5 mL of culture was removed
from each flask to measure the cell density, pH, and Nuc activity
with the FRET assay. Cell densities (OD at 600 nm) were
measured in Thermo Spectronic Genesys20. The culture that
remained after measuring cell density was filter sterilized and
assayed for Nuc activity using the FRET assay described above in
triplicate. The pH of the remaining sterile conditioned media was
measured using an Acumet AB15 pH meter (Fisher Scientific).
Microtiter biofilm assays for controlled nuc expression
experiment
A modified microtiter assay was developed to assess biofilm
formation and Nuc activity levels. Briefly, overnight cultures of
strains grown in TSB supplemented with 0.2% glucose were
subcultured at 1:1000 into 66% TSB supplemented with 0.2%
glucose. After growing cultures at 37uC for ,1 hr with shaking
(200 rpm), 1 mL aliquots were transferred to 24-well tissue culture
treated polystyrene plates (Corning 3548). For aTET induction
experiments, a total of eight wells per aTET concentration were
assayed for each strain. Plates were grown at 37uC with shaking
(200 rpm) for 15 hr. To measure Nuc activity in the wells, 400 ml
of culture was removed and the cultures were pooled according to
test condition. Bacteria were removed using 0.22 mm filters and
Nuc activity was measured using the FRET assay. To quantify
biofilm formation, remaining culture was removed by gentle
aspiration, wells were washed three times with 1 ml of water,
stained with 0.1% crystal violet for 10 min, and again washed
three times with 1 ml of water. After solubilizing the bound crystal
violet in 1 ml of 2-propanol, 200 ml was transferred to a 96-well
plate and OD at 615 nm was measured in a plate reader.
Reported relative biomass is the average of eight wells.
Microtiter biofilm assays for nuc versus biomass
correlation
Overnight cultures grown in BHI were subcultured at 1:1000
into BHI supplemented with 0.4% glucose. After growing cultures
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(eight wells per strain) were transferred to 24-well tissue culture
treated polystyrene plates (Corning 3548). Plates were grown at
37uC with shaking (200 r.p.m.) for 15–16 hr. To measure Nuc
activity in the wells, 400 ml of culture was removed from each well
and the cultures were pooled according to strain. Bacteria were
removed using 0.22 mm syringe tip filters and nuclease activity was
measured in triplicate using the FRET assay at a substrate
concentration of 2 mM. Biomass was quantified using a slightly
modified staining procedure that incorporated a single washing
step after cultures were removed from the wells, since the nuc single
and nuc sigB double mutant biofilms were found to detach from the
plates in sheets during the multiple washing steps of a standard
assay. Specifically, the remaining culture was removed from the
wells by gentle aspiration using a 26.5 gauge needle with the bevel
turned toward the wall of the well and wells were washed with
1 ml of water and stained with 200 ml of 0.1% crystal violet for
15 sec. After removing unbound crystal violet by aspiration,
bound crystal violet was solubilized in 1 ml of 2-propanol and
200 ml was transferred to a 96-well plate and OD at 615 nm was
measured in a plate reader. This modified procedure was used for
all of the mutant strains, not just the nuc and nuc sigB double
mutants. Reported relative biomass are the average of eight wells.
Flow cell biofilm assays
Flow cell biofilms were prepared in a similar manner as
described [9] with some modifications. Briefly, S. aureus cultures
were grown overnight in 5 mL TSB and diluted 1:10 in sterile
water. Flow cell chambers were inoculated with 1 mL of the
diluted culture and bacteria were allowed to attach to acid-etched
glass coverslips for 1 hr at room temperature. Laminar flow was
initiated at a rate of 3.75 rpm, and the flow cells and media were
incubated at 37uC. Biofilm growth media consisted of 2% TSB
supplemented with 0.2% glucose, and when required, plasmids
were maintained at an antibiotic concentration of 1 mg/mL. For
imaging, live/dead staining was performed using the live stain
SYTO9 and dead stain Toto3 or ToPro3 (as indicated) at a
concentration of 1 mM in sterile PBS, as instructed in the BacLight
live/dead staining kit (Invitrogen). Confocal laser scanning
microscopy (CLSM) was performed on a Nikon Eclipse E600
microscope using the Radiance 2100 image capturing system
(Biorad). Image acquisition was performed with the Laser Sharp
2000 software (Zeiss), and images were processed using the
Volocity program (Improvision). Statistical analysis on flow cell
biofilms was done using the COMSTAT program [87].
Extracellular DNA isolation
Strains for eDNA preparations were grown overnight in TSB at
37uC shaking at 200 RPM. Fresh media was inoculated at a
1:1000 dilution and grown for 4 hr with shaking at 37uCt oa nO D
at 600 nm of 2.0. 5 mL of each culture was collected and filter
sterilized to remove cells. Proteins were extracted from the
supernatants using 1 volume of Phenol/Chloroform/Isoamyl
alcohol (Roche, Indianapolis) followed by centrifugation for
15 min at 3,7256 g to separate phases. DNA was precipitated
by addition of 2.5 volumes 100% ethanol and 1/10 volume 3 M
sodium acetate to the aqueous phase. Precipitations were
incubated overnight at 220uC and spun down the following day
at 22,0006g for 15 minutes, followed by a wash with cold 70%
ethanol. Pellets were air dried and resuspended in TE buffer.
eDNA samples were run on 1.0% agarose gels with 1 kb plus
DNA ladder (Invitrogen, Carlsbad, CA). Genomic DNA used as a
control for size comparison was prepared by lysis of S. aureus cells
with Lysostaphin (Ambi Products, Purchase, NY) for 1 hr at 37uC
followed by purification of chromosomal DNA with the Puregene
Yeast/Bacteria Kit B (Qiagen, Maryland) according to the
manufacturer’s protocol. Gels were stained with ethidium bromide
to visualize high MW DNA.
DNase zymography
An overnight culture was used to inoculate 20 mL TSB at an
initial OD at 600 nm of 0.1. Cultures were allowed to grow for
approximately 24 hrs at 37uC with shaking at 200 rpm. Cell-free
spent media was prepared by filtering through a 0.22 mM syringe
filter (Millex-GS). Spent media was diluted 1:5 in TSB and then
mixed with an equal volume of SDS-PAGE sample buffer without
b-mercaptoethanol. 7.5 ml was electrophoresed on a 12% SDS-
PAGE that included 200 mg/mL heat-treated salmon sperm DNA
(Invitrogen). To remove SDS following electrophoresis, gels were
washed with 50 mL portions of 2.5% (v/v) Triton X-100 in distilled
water (2 times, 10 min each), 2.5% Triton X-100 in 50 mM Tris-
HCl, pH 7.4, buffer (2 times, 10 minutes each), and Tris buffer
alone (2 times, 10 min each). After washing, gels were placed in
50 mL of Tris buffer and incubated at 37uC for 15 min. Gels were
stained in ethidium bromide for 10 minutes, destained by rinsing
36in distilled water, and imaged using a Gel Doc 2000 (Bio-Rad).
Immunoblots for Nuc in spent media
S. aureus strains were grown overnight in TSB containing
appropriate antibiotics. Overnight cultures were diluted to an OD
at 600 nM of 0.1 in 5 mL TSB containing antibiotics and grown
with shaking at 37uC for 15 hr. Cells were removed by
centrifugation, and the supernatant was clarified using a 0.22 mm
Spin-X centrifuge filter (Corning). Filtered supernatants weremixed
1:1 with SDS-PAGE loading buffer, and 5 mL of each sample was
electrophoresed on 12%SDS-PAGE.Theproteinsweretransferred
to nitrocellulose or Immobilon-P PVDF membranes (Millipore)
using a Protean II device (Bio-Rad Laboratories). Membranes were
blocked overnight at 4uC with 5% milk in Tris-buffered saline
(20 mM Tris-HCl, pH 7.0, with 137 mM NaCl) containing 0.1%
Tween 20 (TBST). Sheep anti-DNase IgG conjugated to horserad-
ish peroxidase (Toxin Technology, Sarasota, FL) was diluted
1:2,500 in 5% milk in TBST and incubated with the membranes at
room temperature for 2 hours. Membranes were washed with
agitation for 15 min, twice for 5 min with TBST, and developed
with SuperSignal West Pico chemiluminescent substrate followed
by exposure to X-ray film. Concentrations of protease inhibitors
were as follows: 1 mM EGTA, 200 mM PMSF, and 10 mM E-64.
Supporting Information
Figure S1 Processing of Nuc protein. On each panel the
Nuc protein is labeled as the processed forms NucB or NucA. For
panels A and B, LAC WT and strains with mutations in the nuc
gene and agr and sigB regulators were grown 18 hr in TSB, and
cells were removed by filtration. An additional culture was
prepared with complemented nuc mutant. A. Immunoblot for
Nuc. B. DNA zymography. C. An immunoblot of the spent media
from the LAC DsigB mutant grown with protease inhibitors E64,
EGTA, PMSF, or a cocktail of these three inhibitors (PIC).
(TIF)
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